Product Images Sacubitril And Valsartan

This text provides information on a medication with NDC 31722-673-60, containing 24 mg of sacubitril and 26 mg of valsartan in each tablet. It is for prescription use only and comes in a bottle of 60 tablets. The usual dosage should be followed as per prescribing information. The tablets should be stored at 20-25°C, protected from moisture, and kept out of reach of children. The manufacturer is Camber Pharmaceuticals, Inc., with contact information provided. The medication is manufactured by Hetero Labs Limited in Hyderabad, India.*

This is information on Sacubitril and Valsartan Tablets, each containing 49 mg of sacubitril and 51 mg of valsartan. The usual dosage instructions are not provided, so it is recommended to consult the prescribing information. The tablets should be stored at 20° to 25°C and protected from moisture. The manufacturer contact information is available for further inquiries.*

This text contains information about Sacubitril and Valsartan Tablets manufactured by Camber Pharmaceuticals, Inc. The tablets each contain 97 mg of sacubitril and 103 mg of valsartan. The usual dosage information is available in the prescribing information. The tablets should be stored at 20° to 25°C to protect from moisture. The contact number for the U.S. is provided, along with manufacturing details for Camber Pharmaceuticals. The tablets are manufactured by Hetero Labs Limited in Hyderabad, India.*

This document presents data analysis from the PARADIGM-HF clinical trial comparing the efficacy of Sacubitril and Valsartan versus Enalapril in reducing the time to first occurrence of cardiovascular death or heart failure hospitalizations. The figures show hazard ratios and confidence intervals for both outcomes over a span of 1260 days since randomization. These results suggest a significant benefit of Sacubitril and Valsartan over Enalapril in reducing the risk of cardiovascular events in heart failure patients.*

The text provides a detailed breakdown of the subgroup percentages within a study comparing Sacubitril and Valsartan against Enalapril. It shows various demographics, including age groups, gender distribution, weight categories, racial backgrounds, regions, NYHA class, estimated GFR levels, presence of diabetes, systolic blood pressure ranges, ejection fraction percentages, presence of atrial fibrillation, NT-pro BNP levels, hypertension status, and prior use of ACE inhibitors. The hazard ratio analysis is presented for each subgroup, offering valuable insights into the effectiveness and outcome differences among the different subgroups.*

This text appears to be a statistical data table showing percentages related to the use of ARB (angiotensin II receptor blockers), aldosterone antagonists, outcome of hospitalization for heart failure, time since diagnosis of heart failure, cause of heart failure, and comparison of outcomes between Sacubitril and Valsartan versus Enalapril. It provides information on the population percentages and hazard ratios for various scenarios related to heart failure and medication usage.*